Leerink downgraded CymaBay Therapeutics to Market Perform from Outperform with a $32.50 price target after Gilead Sciences (GILD) announced an agreement to acquire Cymabay for $32.50 per share in cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY:
- Biotech Alert: Searches spiking for these stocks today
- CymaBay downgraded to Market Perform from Outperform at LifeSci Capital
- CymaBay downgraded to Neutral from Buy at UBS
- CymaBay downgraded to Neutral from Overweight at Piper Sandler
- CymaBay downgraded to Neutral from Buy at BTIG
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue